Oct 23 (Reuters) - Cyclacel Pharmaceuticals Inc
:
* CYCLACEL PHARMACEUTICALS REPORTS NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 EORTC-NCI-AACR SYMPOSIUM
* CYCLACEL PHARMACEUTICALS - INTERIM PHASE 2 DATA, FADRACICLIB WELL TOLERATED IN COHORT 8 WITH COMMON ADVERSE EVENTS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.